Fulgent Genetics Inc Stock News

In a report released today, Erin Wright from Credit Suisse maintained a Hold rating on Covetrus (CVET), with a price target of $10.00. The company's

In a report released today, Erin Wright from Credit Suisse maintained a Hold rating on Covetrus (CVET – Research Report),

Fulgent Genetics, Inc.'s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic...

The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community

The company is currently accepting samples directly to its BSL-2 certified lab in Temple City, California, versus previously accepting extracted RNA samples through third party laboratories. With the

Q4 2019 Fulgent Genetics Inc Earnings Call

BioNTech SE (NASDAQ:BNTX) +55% on teaming up with Pfizer teams to develop COVID-19 vaccine.Co-Diagnostics (NASDAQ:CODX) +45% as FDA to allow states to authorize coronavirus tests.Neon Therapeutics (

Fulgent’s NGS test will be one of the market’s first diagnostic tests for the COVID-19 virus developed based on NGS technology. Fulgent and MedScan will begin accepting specimens for testing this

Companies in the Services sector have received a lot of coverage today as analysts weigh in on Fulgent Genetics (FLGT) and Hms Holdings (HMSY). Fulgent

Fulgent Genetics (NASDAQ:FLGT) reported Q4 results.Quarterly Results • Earnings per share were up 500% over the past year to $0.04, which in line with the estimate.• Revenue of $8,387,000 up by 47

Fourth Quarter 2019 Results: Revenue totals $8.4 million, growing 48% year over yearBillable tests delivered total 13,977, growing 118% year over yearGross Margin improves more.

NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Fulgent Genetics, Inc. (NASDAQ:FLGT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 4

Perthuis previously held the role of Vice President of Commercial Operations with Fulgent since joining the company in May of 2017. In his new role, Perthuis will continue to lead the company’s glo

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccin